Senti Biosciences Holdings posted a Q2 net loss of USD 12.75 million, narrowing from USD 14.73 million a year earlier.
Research and development expense fell 22.56% to USD 7.77 million, driven by lower SENTI-202 external services, personnel, and facilities costs.
General and administrative expense was little changed at USD 6.74 million, as higher external services costs offset lower personnel and facilities spending.
Other income dipped to USD 1.74 million from USD 2.07 million, as GeneFab sublease income fell to USD 996,000.
Cash and cash equivalents totaled USD 6.5 million at June 30, 2026; it flagged substantial doubt about going concern within one year.
SNTI•
